Cue Biopharma, Inc. Other Noncash Income
Cue Biopharma, Inc. (CUE) reported Other Noncash Income of $68.00 thousand for the 9-month period ending 2019-09-30, per its 10-Q filed 2020-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncome · last filed 2020-11-09
- Cue Biopharma, Inc. other noncash income for the quarter ending 2019-09-30 was $67.00K.
| Period end | Other Noncash Income 3 month | Other Noncash Income 6 month | Other Noncash Income 9 month |
|---|---|---|---|
| 2019-09-30 | $67.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $68.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $1.00K 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |